Literature DB >> 3403218

Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients.

I Rainero1, M Gilli, T De Gennaro, I Chiadò, M Delsedime, A Riccio, B Bergamasco.   

Abstract

The principal peripheral pharmacokinetic parameters of the levodopa/carbidopa association were investigated in 11 healthy volunteers and in 16 patients at various stages of Parkinson disease, with and without the on-off phenomenon. After oral administration of a standard dose of drug (levodopa 250 mg + carbidopa 25 mg) the peak plasma concentrations, peak onset time and area under the curve/time proved to be similar across the groups. There was no difference in peripheral pharmacokinetics of the association between parkinsonian patients with swings in response and those without.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3403218     DOI: 10.1007/bf02334049

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  11 in total

1.  Fluctuations in DOPA decarboxylase activity with age.

Authors:  J Awapara; S Saine
Journal:  J Neurochem       Date:  1975-04       Impact factor: 5.372

2.  Patterns of clinical response and plasma dopa levels in Parkinson's disease.

Authors:  E S Tolosa; W E Martin; H P Cohen; R L Jacobson
Journal:  Neurology       Date:  1975-02       Impact factor: 9.910

3.  Variability of L-dopa absorption in man.

Authors:  D N Wade; P T Mearrick; D J Birkett; J Morris
Journal:  Aust N Z J Med       Date:  1974-04

4.  Absorption and metabolism of levodopa.

Authors:  W B Abrams; C B Coutinho; A S Leon; H E Spiegel
Journal:  JAMA       Date:  1971-12-27       Impact factor: 56.272

Review 5.  Pharmacokinetics of levodopa.

Authors:  J G Nutt; J H Fellman
Journal:  Clin Neuropharmacol       Date:  1984       Impact factor: 1.592

6.  On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

Authors:  R J Hardie; A J Lees; G M Stern
Journal:  Brain       Date:  1984-06       Impact factor: 13.501

7.  Systemic activity of orally administered L-dopa in the elderly Parkinson patient.

Authors:  M A Evans; E J Triggs; G A Broe; N Saines
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

8.  Simultaneous determination of carbidopa, levodopa and 3,4-dihydroxyphenyl-acetic acid using high-performance liquid chromatography with electrochemical detection.

Authors:  E Nissinen; J Taskinen
Journal:  J Chromatogr       Date:  1982-09-10

9.  Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms.

Authors:  P S Papavasiliou; F H McDowell; Y Y Wang; V Rosal; S T Miller
Journal:  Neurology       Date:  1979-02       Impact factor: 9.910

10.  Control of on/off phenomenon by continuous intravenous infusion of levodopa.

Authors:  N Quinn; J D Parkes; C D Marsden
Journal:  Neurology       Date:  1984-09       Impact factor: 9.910

View more
  3 in total

1.  Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.

Authors:  Agnieszka Ciesielska; Nitasha Sharma; Janine Beyer; John Forsayeth; Krystof Bankiewicz
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

Review 2.  Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.

Authors:  Aravind Mittur; Suneel Gupta; Nishit B Modi
Journal:  Clin Pharmacokinet       Date:  2017-09       Impact factor: 6.447

3.  Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.

Authors:  Marios Politis; Kit Wu; Clare Loane; David J Brooks; Lorenzo Kiferle; Federico E Turkheimer; Peter Bain; Sophie Molloy; Paola Piccini
Journal:  J Clin Invest       Date:  2014-02-17       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.